Interpreting results from next-generation genomic sequencing of cancer, and identifying the right drug for the right patient, is a challenge for many cancer specialists today. Join leading global experts for a new educational series from MSK, where we’ll take a deep dive into each of the major cancer signaling pathways and discuss the nuances of precision therapies—with the aim of enhancing our collective understanding. In this quarterly series, we will begin with KRAS and subsequently focus on BRAF, EGFR, HER2, BRCA and HRD, RET/ALK, FGFR, and emerging pathways.
| Register Now |
| • | Dr. Sewanti Limaye: Director of Medical & Precision Oncology, Sir HN Reliance Foundation Hospital, Mumbai |
| • | Dr. Mrinal Gounder: Medical Oncology, Early Phase Trials, MSK, New York |
| • | Dr. Vijay Agarwal: Medical Oncologist, Apollo Hospitals, Bangalore |
| • | Dr. Ullas Batra: Chief of Thoracic Medical Oncology, Rajiv Gandhi Cancer Institute, New Delhi |
| • | Dr. Debyani Chakravarty: Clinical Cancer Genomics, MSK, New York |
| • | Dr. Bhuvan Chugh: Senior Consultant Medical Oncology, Max Hospital, New Delhi |
| • | Dr. Yonina Murciano-Goroff: Medical Oncology, Early Phase Trials, MSK, New York | • | Dr. T. Raja: Director of Medical Oncology, Apollo Cancer Centre, Chennai |
| • | Dr. Gregory Riely: Thoracic Medical Oncology, MSK, New York |
| • | Dr. Rona D. Yaeger: Gastrointestinal Medical Oncology, MSK, New York |
Download event brochure to see featured panelists and moderators.
Register Now
Wednesday, 26 April, 2023
6:00–7:45 p.m. IST/ 8:30–10:15 a.m. ET